Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Purpose: The primary objective of this study is to determine if chemotherapy with carboplatin
and temozolomide significantly affects the response rates, or size of disease, in patients
with brain metastases, originating from cancer in other parts of the body, compared to
patients who have already been treated with radiation. Survival, causes of death, recurrence
of disease in the central nervous system, toxicity, and quality of life will all be measured
as secondary objective in this study.